Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals. Ginkgo Bioworks has a partnership with Selecta Biosciences, Inc. to develop ImmTOR technology platform. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Ginkgo Bioworks Holdings, Inc.

Grow by Ginkgo

At Ginkgo, we use biology to grow the future. Companies across industries leverage our platform to design, develop, and optimize products for a breadth of commercial applications. We help our partners grow key ingredients for vaccines, crops that rely less on fossil fuel-based fertilizers, plant-based meat that tastes like the real thing, materials for the next generation of circular fashion, and so much more. We know our unique experiences, ideas, and perspectives are essential to our success and enable us to make biology easier to engineer and ensure equitable distribution of the benefits of our platform. As such, we seek to ensure that DEI is in our DNA, continuing to grow an inclusive culture and diverse workforce. Let's make biology easier to engineer and join our team.

Synlogic

Empede Capital

General Atlantic

Y Combinator

Bill Gates

Cascade Investment

T. Rowe Price

Viking Global Investors

Illumina

Ginkgo Bioworks, Inc.

Today on Foundry Theory we're all about iGEM - the heart of synthetic biology.
https://hubs.la/Q02kdx3q0

Humans of Ginkgo Bioworks is an interview series, featuring Sudeep Agarwala, that dives into the exciting technology at Ginkgo.

Today, we've released the final part of our three-part interview with Ginkgo’s head of ALE, Simon Trancart!

In Part 3, Simon discusses how our partners are working with us to make automated ALE at Ginkgo accessible to new industries.

Read it here:
https://hubs.la/Q02k9M_00

Catch up on Part 1 here: https://hubs.la/Q02k9Pbj0

And Part 2 here: https://hubs.la/Q02k9M8z0

Thank you, Elaine Watson and AgFunder, for the great featuring of our offering and strategic collaborations with Ginkgo Bioworks, Inc. and dsm-firmenich toward launching our products.

Tal Zeltzer | Sandro Tomita | Fredrik Hjelmqvist | David Borhani | Kevin Madden

#DOD Biomanufacturing RFP is out 👇🏻👇🏻 

https://lnkd.in/e6Bk8jtW

When I started my NSC detail, I knew very little about #biomanufacturing but after drinking from a firehose on the topic for a few months I came to see the plethora of ways this growing ecosystem of bio companies and technologies can strengthen America; from improving sustainability, strengthening supply chains, and growing the economy.

This RFP is an opportunity to invest in building Biomanufacturing capacity across the country. It's great to see it posted.

Congrats to all the people who worked hard to get this done: Kate Sixt Peter Emanuel Michelle Rozo Kirsten Kulcsar Weand, PhD Anne Cheever Georgia Lagoudas Sarah Glaven Douglas Friedman Robert Fisher Ben Buchanan Ishan K. Sharma and many others.

Check out Nita Madhav and friends as they figure out how to ensure we don't have another major biological event in our lifetimes. https://lnkd.in/eN94t7_F

Die Teilnehmer*innen der Delegationsreise in die USA hatte die Gelegenheit, Ginkgo Bioworks, Inc. zu besuchen und einen Einblick in deren Entwicklung und Labors zu erhalten.

Ginkgo Bioworks ist ein Biotech-Unternehmen, das sich auf die gentechnische Herstellung von Bakterien für industrielle Anwendungen spezialisiert hat. Die Expertise des Unternehmens erstreckt sich über die Entwicklungen von Mikroorganismen bis hin zur Herstellung von synthetischen Zellen, die schließlich die Grundlage für die Produktion verschiedener Materialien bilden können.

Der Besuch ermöglichte es neueste Fortschritte und Innovationen im Bereich der Genomtechnologie zu erkunden. Die Labors boten Einblicke in die Präzisionsarbeit, die hinter der Entwicklung maßgeschneiderter Mikroorganismen steht. Philipp Heuermann zeigten die internationalen Perspektiven von Ginkgo Bioworks auf.

VDMA, Wittenstein Stiftung, Universität Hohenheim, Universität Stuttgart, Baden-Württemberg International (BW_i), Thomas Bauernhansl

This is biology's century.

Just as computer science transformed the 20th century, biological science will transform the 21st. 

Alison Snyder explores growing global competition to harness that science to develop and make biotechnology products at scale.

More in In Axios Science👇🏾 

https://lnkd.in/eakijuky

“Biology is the only substrate, the only scientific discipline, that is capable of solving the great challenges of the world—food security, climate change, human health—all of those are biological problems”🦠🧬🧫🌱🍄🐝

Enjoyed chatting with Mark Sullivan at Forbes about the intersection of AI and Biology. 

https://lnkd.in/eZH8EZQ6

Thanks to the The Burn Bag and Andrea Ochoa for a great conversation about biology as a domain of operations, bio-intelligence (BIOINT), and the coming era of biosecurity.

Listen here: bit.ly/49muHGI

Ginkgo Bioworks, Inc.

Are your new product development efforts limited by commercially available enzyme technology? What if you could discover or design the exact enzyme needed to unlock your next innovation? See how one of our customers utilized Ginkgo's scale, automation, and AI algorithms to discover their unique enzyme. 

Interested? Contact us here to learn more! https://hubs.la/Q02jV4hY0

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
account payables	2.44M -	13.89M 469.62%	8.19M 41.06%	10.45M 27.62%	9.32M 10.79%
accumulated other comprehensive income loss			-1.72M -	-2.63M 53.47%	1.48M 156.38%
cash and cash equivalents	495.29M -	380.80M 23.12%	1.55B 307.04%	1.32B 15.11%	948.86M 27.89%
cash and short term investments	495.29M -	380.80M 23.12%	1.55B 307.04%	1.32B 15.11%	948.86M 27.89%
common stock	79K -	129K 63.29%	161K 24.81%	190K 18.01%	199K 4.74%
deferred revenue		28.82M -	33.24M 15.32%	47.82M 43.85%	48.49M 1.42%
deferred revenue non current		99.65M -	155.99M 56.54%	174.77M 12.04%	158.06M 9.56%
deferrred tax liabilities non current		12.68M -	154.58M 1,119.31%
goodwill	1.86M -	1.86M 0%	21.31M 1,047.66%	60.21M 182.52%	49.24M 18.22%
goodwill and intangible assets	5.70M -	5.15M 9.63%	42.95M 733.90%	171.25M 298.68%	131.98M 22.93%
intangible assets	3.84M -	3.29M 14.29%	21.64M 557.01%	111.04M 413.08%	82.74M 25.49%
inventory		2.74M -	3.36M 22.88%	4.36M 29.80%	46K 98.95%
long term debt		16.52M -	22.28M 34.90%	413.26M 1,754.58%	221.84M 46.32%
long term investments	107.25M -	103.12M 3.85%	115.23M 11.74%	113.73M 1.30%	132.89M 16.84%
net debt	-495.29M -	-363.80M 26.55%	-1.53B 319.73%	-873.20M 42.81%	-707.09M 19.02%
net receivables	7.68M -	24.17M 214.85%	149.90M 520.08%	82.47M 44.99%	31.74M 61.51%
other assets	9.31M -
other current assets	8.96M -	1.44M 83.92%	698K 51.56%	47.46M 6,699.14%	21.10M 55.53%
other current liabilities	37.63M -	30.02M 20.23%	92.58M 208.41%	85.36M 7.80%	86.11M 0.88%
other liabilities	16.77M -
other non current assets	-176.09M -	5.60M 103.18%	43.99M 685.12%	88.72M 101.69%	1.50M 98.31%
other non current liabilities		3.03M -	35.99M 1,087.07%	42.06M 16.86%	24.43M 41.91%
othertotal stockholders equity	834.08M -	929.13M 11.40%	3.80B 309.51%	6.14B 61.28%	6.39B 4.07%
preferred stock	177K -
property plant equipment net	63.13M -	121.44M 92.35%	145.77M 20.04%	715.53M 390.87%	397.22M 44.49%
retained earnings	-341.27M -	-467.88M 37.10%	-2.30B 391.14%	-4.40B 91.38%	-5.29B 20.30%
short term debt		485K -	747K 54.02%	29.33M 3,826.64%	19.93M 32.04%
short term investments
tax assets		13.30M -
tax payables
total assets	697.32M -	675.15M 3.18%	2.07B 206.74%	2.54B 22.61%	1.67B 34.42%
total current assets	511.93M -	426.54M 16.68%	1.72B 303.96%	1.45B 15.84%	1.00B 30.92%
total current liabilities	40.07M -	73.22M 82.71%	134.76M 84.05%	172.96M 28.35%	163.86M 5.26%
total debt		17.00M -	23.03M 35.45%	442.59M 1,821.79%	241.77M 45.37%
total investments	107.25M -	103.12M 3.85%	115.23M 11.74%	113.73M 1.30%	132.89M 16.84%
total liabilities	195.47M -	205.10M 4.93%	503.61M 145.54%	803.04M 59.46%	568.19M 29.25%
total liabilities and stockholders equity	697.32M -	675.15M 3.18%	2.07B 206.74%	2.54B 22.61%	1.67B 34.42%
total non current assets	176.09M -	248.61M 41.19%	347.94M 39.96%	1.09B 213.05%	663.59M 39.08%
total non current liabilities		131.88M -	368.85M 179.69%	630.08M 70.82%	404.33M 35.83%
total stockholders equity	493.06M -	461.38M 6.43%	1.51B 226.28%	1.74B 15.34%	1.10B 36.81%

NYSE:DNA

Ginkgo Bioworks Holdings, Inc.

Last Close

0.86

03/05 20:00

Market Cap

2.73B

Beta: 0.89

Volume Today

54.56M

Avg: 18.92M

PE Ratio

−2.78

PFCF: −6.38